Henry Schein, Inc. (NASDAQ:HSIC) Shares Sold by Atom Investors LP

Atom Investors LP trimmed its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 27.3% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 22,741 shares of the company’s stock after selling 8,543 shares during the period. Atom Investors LP’s holdings in Henry Schein were worth $1,658,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. ING Groep NV acquired a new position in Henry Schein in the 3rd quarter worth approximately $63,226,000. Thompson Siegel & Walmsley LLC acquired a new stake in Henry Schein in the 2nd quarter worth approximately $46,683,000. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Henry Schein during the 3rd quarter worth $43,740,000. Southpoint Capital Advisors LP raised its holdings in Henry Schein by 30.0% in the 3rd quarter. Southpoint Capital Advisors LP now owns 2,600,000 shares of the company’s stock valued at $189,540,000 after acquiring an additional 600,000 shares in the last quarter. Finally, Bank of Montreal Can increased its position in shares of Henry Schein by 365.6% during the third quarter. Bank of Montreal Can now owns 711,487 shares of the company’s stock valued at $52,095,000 after purchasing an additional 558,689 shares during the period. Institutional investors and hedge funds own 96.62% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. UBS Group cut their price objective on Henry Schein from $75.00 to $72.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. StockNews.com raised shares of Henry Schein from a “sell” rating to a “hold” rating in a report on Thursday, November 7th. Evercore ISI boosted their target price on Henry Schein from $70.00 to $74.00 and gave the stock an “in-line” rating in a report on Tuesday, October 8th. Barrington Research reaffirmed an “outperform” rating and set a $82.00 price target on shares of Henry Schein in a report on Wednesday, November 6th. Finally, JPMorgan Chase & Co. reduced their price objective on Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Six research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Henry Schein has a consensus rating of “Moderate Buy” and a consensus target price of $79.38.

Henry Schein Stock Down 0.7 %

NASDAQ HSIC opened at $76.50 on Tuesday. The stock has a market capitalization of $9.54 billion, a P/E ratio of 31.48, a price-to-earnings-growth ratio of 2.21 and a beta of 0.87. Henry Schein, Inc. has a 52 week low of $63.67 and a 52 week high of $82.63. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42. The stock has a fifty day moving average of $71.57 and a 200-day moving average of $69.88.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of $1.17 by $0.05. The firm had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.24 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The company’s revenue was up .4% on a year-over-year basis. During the same period last year, the company earned $1.32 earnings per share. On average, equities research analysts forecast that Henry Schein, Inc. will post 4.78 EPS for the current year.

Insider Transactions at Henry Schein

In other news, SVP Lorelei Mcglynn sold 21,035 shares of the firm’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $69.30, for a total value of $1,457,725.50. Following the transaction, the senior vice president now directly owns 71,833 shares in the company, valued at $4,978,026.90. This trade represents a 22.65 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Michael S. Ettinger sold 12,240 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $75.00, for a total value of $918,000.00. Following the completion of the sale, the chief operating officer now owns 87,706 shares of the company’s stock, valued at $6,577,950. This represents a 12.25 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is owned by corporate insiders.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.